Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.

@article{Erem2009BloodCA,
  title={Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.},
  author={Cihangir Erem and Irfan Nuhoğlu and Mustafa Yilmaz and Mustafa Eray Kocak and Aslihan Ertaban Demirel and Ozge Ucuncu and H Onder Ersoz},
  journal={Journal of endocrinological investigation},
  year={2009},
  volume={32 2},
  pages={169-74}
}
BACKGROUND AND OBJECTIVES Cushing's syndrome (CS) is associated with an increased cardiovascular mortality and morbidity. Chronic endogenous and exogenous hypercortisolism frequently induce a hypercoagulable and thrombotic condition. Little is known about hemostatic features of patients with CS. To our knowledge, plasma tissue factor pathway inhibitor (TFPI) and thrombin-activatable fibrinolysis inhibitor (TAFI) levels in these patients have not been investigated. Therefore, the main purpose of… CONTINUE READING